Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Elemental chlorine or elemental chlorine releasing inorganic...
Reexamination Certificate
2006-03-17
2011-10-04
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Elemental chlorine or elemental chlorine releasing inorganic...
C424S661000, C514S879000
Reexamination Certificate
active
08029826
ABSTRACT:
The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.
REFERENCES:
patent: 4507285 (1985-03-01), Kuhne
patent: 4725437 (1988-02-01), Kuhne
patent: 5877222 (1999-03-01), McGrath
patent: 6086922 (2000-07-01), Kuhne
patent: 2001/0036631 (2001-11-01), McGrath et al.
patent: 2003/0130350 (2003-07-01), Ramesh et al.
patent: 2003/0130357 (2003-07-01), Ramesh et al.
patent: 2003/0158262 (2003-08-01), Ramesh et al.
patent: 2003/0175832 (2003-09-01), Marton et al.
patent: 2005/0129784 (2005-06-01), Kuehne
patent: 2005/0181068 (2005-08-01), McGrath
patent: 2001-078775 (2001-03-01), None
patent: 99/17787 (1999-04-01), None
patent: WO-99-21542 (1999-05-01), None
patent: 01/40517 (2001-06-01), None
patent: 03/048773 (2003-06-01), None
Sorg, O., “Oxidative stress: a theoretical model or a biological reality?” Comptes Rendus Biologies, vol. 327(7), pp. 649-662 (Jul. 2004).
Smith, D.G. et al., “The redox chemistry of the Alzheimer's disease amyloid B peptide,” Biochimica et Biophysica Acta, vol. 1768(8), pp. 1976-1990 (2007).
Zhu, X. et al., “Oxidative stress signalling in Alzheimer's disease,” Brain Research, vol. 1000(1,2), pp. 32-39 (2004).
Adamson et al; Rate And Severity Of HIV-Associated Dementia (Had): 1999Mol. Med. (5) 98-109.
Liu et al. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain.J. Neurovirol. 2000,6(suppl 1): S70-81.
Fischer-Smith et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection,J. Neurovirol, 2001. 7:528-541.
McGrath et al. Development of WF10, a novel macrophage-regulating agent.Curr. Opin. Investig. Drugs2002,3:365-373.
Dimethaid Research Inc.—WF10, Immune Regulation, p. 1-2, http://www.dimethaid.com/products/wf10.asp.
McGrath, et al. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol. Jun. 2004; 229(2): 149-58.
Srisupundit, et al. The efficacy of chemically-stabilized chlorite-matrix (TCDO) in the management of late postradiation cystitis. J Med Assoc Thai. Aug. 1999; 82(8): 798-802.
Ennen, et al. Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen. AIDS. Sep. 1993; 7(9): 1205-12.
Kempf Sr., et al. Comparative study on the effects of chlorite oxygen reaction product TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClO2) with equimolar chlorite content on bone marrow and peripheral blood of BDIX rats. Drugs Exp Clin Res. 1993; 19(4): 165-74.
Habermann E, et al. [Oxoferin and sodium chlorite—a comparison] Klin Wochenschr. Jan. 4, 1989;67(1):20-5. German. , PMID: 2921839.
Elstner EF [Heme activated oxidations using the chlorite-oxygen complex “TCDO” (Oxoferin)—an overview] Z Naturforsch [C]. Nov.-Dec. 1988;43(11-12):893-902. German., PMID: 3245879.
Weise K. et al. Clinical experiences with tetrachlorodecaoxide in the local treatment of difficult-to-heal wounds, Aktuelle Traumatol. Oct. 1988;18(5):219-25.
Karrow NA. et al. Evaluation of the immunomodulatory effects of the disinfection by-product, sodium chlorite, in female B6C3F1 mice: a drinking water study.Drug Chem Toxicol. Aug. 2001;24(3):239-58.
Weislow OS. et al. Suppression of extablished Friend virus leukemia by statolon: potentiation of statolon's leukemosuppressive activity by chlorite-oxidized oxyamylose. Infect Immun. Jan. 1975;11(1):129-36.
Billiau A. et al. Antiviral activity of chlorite-oxidized oxyamylose, a polyacetal carboxylic acid. J Virol. Mar. 1970;5(3):321-8.
Akiyama et al. Inflammation and Alzheimer's disease, Neurobiol Aging. May-Jun. 2000; 21(3):383-421.
Alexianu et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression, Neurology. Oct. 9, 2001; 57(7):1282-9.
Anderson et al. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol. Jul. 2002; 72(1):101-6.
Appel et al. Evidence for autoimmunity in amyotrophic lateral sclerosis,J. Neurol. Sci, 1993. 118:169-174.
Cremer et al. Antibody titers to coxsackieviruses in amyotrophic lateral sclerosis,N. Engl. J. Med, 1976. 295(2):107-108. (Letter).
Diesing et al. HIV-1-associated dementia: a basic science and clinical perspective,AIDS Read, 2002. 12:358-368.
Engelthardt .et al. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis,Arch. Neurol. 1990. 47:1210-1216.
Fiala et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier,Eur. J. Clin. Invest. 2002,32:360-371.
Giese et al. Differential effects on innate versus adaptive immune responses by WF10, Cell Immunol. Jun. 2004;229(2):149-58.
Glass et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.Ann. Neurol, 1995. 38:755-762.
Hansen et al. High-dose stabilized chlorite matrix WF10 prolongs cardiac xenograft survival in the hamster-to-rat model without inducing ultrastructural or biochemical signs of cardiotoxicity. Pharmacol Toxicol. Aug. 2001; 89(2):92-5.
Hayashi et al. Pathological study of the diffuse myelin pallor in the anterolateral columns of the spinal cord in amyotrophic lateral sclerosis,J. Neurol. Sci. 2001,188:3-7.
Hensley et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.J. Neurochem, 2002. 82:365-374.
Hirsch et al. The role of glial reaction and inflammation in Parkinson's disease.Ann. N.Y. Acad. Sci, 2003. 991:214-228.
Janssen et al. Nomenclature and research case definitions of neurologic manifestatations of human immunodeficiency virus-type 1 (HIV-1) infection.Neurology. 1991,41:778-785.
Kemp et al. Immunosuppression in xenotransplantation with Wf10. Pharmacol Toxicol. Jun. 2002;90(6):346-8.
Kemp et al. WF10 in xenotransplantation—a potential new approach Transplant Proc. Aug. 2000;32(5):1018-9.
Klaustermeyer et al. Quantitative immunoglobulins and IgG subclasses in patients with corticosteroid-dependent reversible airway obstruction.Ann. Allergy. 1989,63:327-330.
Kott et al. Cell-mediated immunity to polio and HLA antigens in amyotrophic lateral sclerosis.Neurology. 1979,29:1040-1044.
Lehrich et al. Neutralizing antibodies to poliovirus and mumps virus in amyotrophic lateral sclerosis.J. Neurol. Sci. 1974,23:537-540.
MacGowan et al. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.Neurology. 2001. 57:1094-10.
Marshall et al. Cytokine dysregulation associated with exam stress in healthy medical students.Brain Behav. Immun. 1998,12:297-307.
McArthur et al. Dementia in AIDS patients: incidence and risk factors.Neurology, 1993, 43:2245-2252.
McGeer et al. The importance of inflammatory mechanisms in Alzheimer disease.Exp. Gerontol. 1998, 33:371-378.
McGeer et al. Inflammatory processes in amyotrophic lateral sclerosis.Muscle Nerve. 2002,26:459-470.
McGrath et al. Effect of WF10 (TCDO) on antigen presentation.Transplant. Proc. 1998,30:4200-4204.
McGrath et al. Balanced macrophage activation hypothesis: a biological model for development of drugs targeted at macrophage functional states.Pathobiology. 1999, 67:277-81.
Minagar et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis.J. Neurol. Sci. 2002,202:13-23.
Mizutani et al. Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3.J. Neurol. Sci. 2001, (188) 9-11.
Morgan et al. Clinical significance of IgG subclass
Bozicevic Field & Francis LLP
Chandra Shweta
Francis Carol L.
Pak John
The Regents of the University of California
LandOfFree
Chlorite in the treatment of neurodegenerative disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chlorite in the treatment of neurodegenerative disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlorite in the treatment of neurodegenerative disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270144